TrialID,Countries,region_Oceania,manual,study_arm,url,Scientific_title,Conditions,Date_enrollment_format,control_arm,randomisation,blinding,subject_blind,caregiver_blind,investigator_blind,outcome_blind,analyst_blind,prospective,Source_registry,phase_clean,region_Africa,region_N_America,region_L_America,region_Asia,region_Europe,multicentre,primary_purpose,sponsor_type,sample_size,vaccine,conventional,traditional,Bridging_flag,Study_design,Day_inferred,Date_registration_format,Phase,Public_title,Primary_sponsor,Interventions
NCT04454307,NA,Unreported,No,covid,https://clinicaltrials.gov/show/NCT04454307,Safety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients: A Randomized Double Blind Controlled Clinical Trial,COVID-19,2020-07-01,Yes,Yes,Yes,Yes,Yes,No,No,No,Yes,CT.gov,Phase 2,Unreported,Unreported,Unreported,Unreported,Unreported,NA,Treatment,non_industry,100,NA,NA,NA,FALSE,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",TRUE,2020-06-29,Phase 1/Phase 2,Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients,Tanta University,Drug: Tramadol;Other: Standard care delivered in the isolation hospitals.
